Basic and clinical Research for Caveolin as a therapeutic target for urogenital cancer

点击翻译按钮获取中文摘要

Purpose of this research is to elucidate the basic and clinical implication. of caveolin as a therapeutic molecular target for urogenital cancer. We have highlighted the mechanistic analysis of the formation of multi drug resistance for anti-cancer drugs. Expression study of caveolin, multidrug resistance related molecules (MDR, MRP) was performed using cultured cells and clinical samples. Caveolin expression was also analyzed morphologically using transmission electron microscope as a form of caveolae.1)Bladder cancer cell linesParent and induced Adriamycin (ADM) resistant bladder cell lines (T-24 vs T-24/ADM and KK-47 vs KK-47/ADM) were analyzed. Caveolin expression decreased in T-24/ADM compared to T-24 but increased in KK-47/ADM compared to KK-47. Expression level of caveolin protein positively correlated with the number of caveolae detected by TEM. MDR was positive in KK-47/AD. MRP was positive in T-24/ADM and KK-47/ADM. Expression of MDR was positively correlated with caveolin in the process of drug resistance formation.2)Clinical sample of bladder cancerClinical samples were obtained from the patients who showed resistance or recurrence to conventional anticancer drug treatment including ADM. No correlation was observed among the protein expression of caveolin, MDR and MRP3)Prostate cancer cell linesHuman prostate cancer cell lines (PC-3, DU-145, LNCap) were analyzed with the same methods used in the analysis of the bladder cancer, No correlation was observed among the protein expression of cave olin, MDR and MRP